Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.75 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904137 | 0.89 | TBXAS1 (0.62) | TBXAS1EGLN3ALDH1A1CYP19A1PRKCI | |
| SCHEMBL9777196 | 0.88 | TBXAS1 (0.85) | TBXAS1EGLN3CYP19A1PRKCI | |
| SCHEMBL937596 | 0.88 | TBXAS1 (0.95) | TBXAS1PRKCI | |
| SCHEMBL937530 | 0.86 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL1679410 | 0.86 | TBXAS1 (1.00) | TBXAS1 | |
| Ammonia Solution, Strong SCHEMBL7096678 | 0.86 | TBXAS1 (0.81) | TBXAS1EGLN3CYP19A1PRKCI | |
| SCHEMBL2535103 | 0.86 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL10247600 | 0.86 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2532389 | 0.86 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2533366 | 0.86 | TBXAS1 (1.00) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| CN-117843523-A | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-113463074-B | Copper deposition composition and copper deposition method | 广东硕成科技股份有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-108187749-B | Preparation method of multifunctional sponge catalyst for water electrolysis | 潍坊学院 | 2020-06-23 | — | — | CN | claimed |
| CN-106881153-B | The preparation of the organic silicon sphere catalyst of hydrophobic modification and catalyst and application | 中国科学院大连化学物理研究所 | 2019-06-11 | — | — | CN | claimed |
| CN-106881153-A | The preparation and catalyst and application of the organic silicon sphere catalyst of hydrophobic modification | 中国科学院大连化学物理研究所 | 2017-06-23 | — | — | CN | claimed |
| CN-105498834-A | Heterogeneous catalyst and application of heterogeneous catalyst in ammoniation reaction of polyhydroxy compound | DALIAN INST CHEMICAL PHYSICS CAS | 2016-04-20 | — | — | CN | claimed |
| CN-105435842-A | Homogeneous catalyst and application thereof in polyhydroxy compound ammoniation reaction | DALIAN INST CHEMICAL PHYSICS CAS | 2016-03-30 | — | — | CN | claimed |
| CN-104056660-A | Ionic liquid-modified mesoporous material and preparation method | DALIAN CHEMICAL PHYSICS INST | 2014-09-24 | — | — | CN | claimed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | claimed |
| US-4218568-A | HYDROLYSIS OF METHYL FORMATE IN THE PRESENCE OF AN IMIDAZOLE BASE | BASF AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | claimed |
| US-12404221-B2 | Methods of arene alkenylation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3883522-B1 | USE OF A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE FOR REDUCING THE STICKINESS OF A DENTAL IMPRESSION COMPOSITION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-08-29 | — | — | US | disclosed |
| EP-4346741-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| US-7196264-B2 | Dye sensitized solar cell and method for manufacturing dye sensitized solar cell | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196264-B2 | Dye sensitized solar cell and method for manufacturing dye sensitized solar cell | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-0110429-B1 | RETARDERS FOR THE POLYMERISATION OF AZIRIDINE COMPOUNDS | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | disclosed |
| EP-0110429-A2 | Retarders for the polymerisation of aziridine compounds | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | INTS9, PUF60, TAS2R42 | TBXAS1 3950/4885EGLN3 1076/4885ALDH1A1 2914/4885 |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | TBXAS1 4677/4885EGLN3 1260/4885ALDH1A1 1229/4885 |
| US-12404221-B2 | Methods of arene alkenylation | CYBB, CBR3, AHR | TBXAS1 1684/4885EGLN3 1325/4885ALDH1A1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.